As blood cancer wonder-drug Gleevec ages, Novartis is trying to build out indications for follow-up Tasigna. After an up-and-down week for the pair, the Swiss pharma is now short a potential Tasigna label expansion, thanks to a snag in Europe. But a change of heart for the U.K.'s cost watchdog on Gleevec may give the franchise a boost.
When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...
After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun's generic version off the U.S. market until February 2016, Reuters reports. Novartis' U.S. patent expires in July 2015.
After years of struggling for intellectual property rights over cancer drug Glivec in India, Novartis ($NVS) will now have to fight for patent protection in the U.S. as well.
Bring on the discounts, China says. Former health minister Chen Zhu figures Big Pharma will need to give the government a break on drug costs, in exchange for access to a "huge market," Bloomberg reports.
Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
Easter promises to be a nail-biting weekend for Novartis. That's because a final verdict in the big Glivec patent case is due on Monday from India's Supreme Court. So, the Swiss drugmaker will finally win its patent for the cancer treatment--or not.
Novartis and its cancer drug Gleevec had one of those days that starts off not looking so good and then something comes along to turn things around.
India's Supreme Court is expected to rule soon on a patent for Novartis' ($NVS) groundbreaking cancer treatment Gleevec, and Big Pharma and international aid groups are waiting with bated breath to see how it turns out, each for different reasons.
And in a preview of its R&D showcase, the pharma giant--which spent an industry-leading $9.58 billion on R&D last year--offered a bullish assessment of a slate of experimental therapies it believes can break past the $1 billion annual revenue mark.